Pharmacology of Methotrexate

Introduction/Overview

Methotrexate, a structural analogue of folic acid, represents a cornerstone therapeutic agent in both oncology and immunology. Originally developed as a chemotherapeutic drug in the 1940s, its application has expanded significantly to become a first-line disease-modifying antirheumatic drug (DMARD) for numerous autoimmune conditions. This evolution from a cytotoxic agent to an immunomodulator, dependent on dosage regimen, underscores its unique and multifaceted pharmacology. The clinical importance of methotrexate is profound, given its central role in the treatment of malignancies such as acute lymphoblastic leukemia, and chronic inflammatory diseases including rheumatoid arthritis, psoriasis, and Crohn’s disease. A thorough understanding of its pharmacology is essential for optimizing therapeutic efficacy while minimizing the risk of serious toxicity, which remains a significant clinical concern.

Learning Objectives

• Describe the biochemical mechanism of action of methotrexate as an inhibitor of dihydrofolate reductase and its downstream consequences on nucleotide synthesis.
• Explain the key pharmacokinetic properties of methotrexate, including its absorption, distribution, metabolism, and elimination, and how these relate to dosing in different clinical contexts.
• Compare and contrast the high-dose chemotherapeutic and low-dose immunomodulatory applications of methotrexate, identifying the approved indications for each.
• Identify the spectrum of adverse effects associated with methotrexate therapy, from common side effects to life-threatening toxicities, and outline appropriate monitoring and management strategies.
• Analyze critical drug interactions, contraindications, and special population considerations, including use in renal impairment, pregnancy, and pediatric patients.

Classification

Methotrexate is classified within multiple therapeutic and chemical categories, reflecting its diverse applications. The primary classification is as an antimetabolite, specifically an antifolate agent. Within oncology, it is categorized as a cell cycle-specific chemotherapeutic drug, exerting its cytotoxic effects primarily during the S-phase (DNA synthesis phase) of rapidly dividing cells. For autoimmune diseases, it is classified as a disease-modifying antirheumatic drug (DMARD), often termed a conventional synthetic DMARD. Chemically, methotrexate (C₂₀H₂₂N₈O₅) is a derivative of folic acid, wherein the 4-hydroxy group of the pteridine ring is replaced by an amino group and a methyl group is added to the N10 position. This structural modification creates a molecule with significantly higher affinity for its target enzyme than the natural substrate.

Mechanism of Action

The pharmacodynamic effects of methotrexate are primarily mediated through the inhibition of folate-dependent enzymes, leading to a disruption of cellular nucleotide synthesis. The precise consequences of this inhibition vary depending on the dose and cellular context, explaining its dual role as a cytotoxic and immunomodulatory agent.

Primary Biochemical Action: Dihydrofolate Reductase Inhibition

The principal and most well-characterized mechanism involves competitive and high-affinity inhibition of the enzyme dihydrofolate reductase (DHFR). DHFR is responsible for the reduction of dihydrofolate (DHF) to tetrahydrofolate (THF), and the reduction of folate to DHF. THF is an essential cofactor in one-carbon transfer reactions required for the de novo synthesis of purine nucleotides and thymidylate. By inhibiting DHFR, methotrexate causes intracellular depletion of reduced folate cofactors, notably 5,10-methylenetetrahydrofolate. This leads to two critical biochemical disruptions:

1. Inhibition of Thymidylate Synthesis: Thymidylate synthase requires 5,10-methylenetetrahydrofolate as a co-substrate to methylate deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP). Depletion of this cofactor halts dTMP production, leading to “thymineless death” in rapidly proliferating cells due to impaired DNA synthesis and repair.
2. Inhibition of Purine Synthesis: The de novo purine synthesis pathway involves two steps that require folate cofactors: the conversion of glycinamide ribonucleotide (GAR) to formylglycinamide ribonucleotide (FGAR) and the conversion of aminoimidazole carboxamide ribonucleotide (AICAR) to formylaminoimidazole carboxamide ribonucleotide (FAICAR). Inhibition of these steps leads to a depletion of adenosine and guanine nucleotides.

The net result is a cessation of DNA and RNA synthesis, which is particularly cytotoxic to cells with high proliferative rates, such as malignant cells, gastrointestinal mucosal cells, and bone marrow precursors.

Polyglutamation and Intracellular Retention

A critical determinant of methotrexate’s activity and selectivity is its intracellular metabolism. Methotrexate enters cells primarily via the reduced folate carrier (RFC) and, to a lesser extent, by membrane folate receptors. Once inside the cell, it is polyglutamated by the enzyme folylpolyglutamate synthetase (FPGS) by the addition of multiple glutamate residues. Methotrexate polyglutamates (MTX-Glu_n) exhibit two key properties:

• Enhanced Retention: Polyglutamated forms are charged and poorly diffusible, leading to prolonged intracellular retention even after extracellular drug concentrations decline.
• Broadened Enzyme Inhibition: While methotrexate monoglutamate primarily inhibits DHFR, the polyglutamated forms are potent inhibitors of other folate-dependent enzymes, including thymidylate synthase (TS) and enzymes in the purine synthesis pathway (AICAR transformylase and GAR transformylase). This direct inhibition of multiple targets amplifies the antimetabolite effect.

Immunomodulatory Mechanisms

The anti-inflammatory effects observed with low-dose weekly methotrexate regimens in autoimmune diseases are not fully explained by cytotoxic mechanisms, as the doses used are generally lower than those required to cause significant immunosuppression via antiproliferation. Several immunomodulatory mechanisms have been proposed:

• Adenosine Release: Inhibition of AICAR transformylase by methotrexate polyglutamates leads to intracellular accumulation of AICAR. AICAR inhibits AMP deaminase, resulting in increased intracellular AMP levels, which are subsequently converted to adenosine. Adenosine is then released into the extracellular space, where it acts on A_2A receptors on inflammatory cells (e.g., neutrophils, macrophages, lymphocytes). Adenosine receptor activation exerts potent anti-inflammatory effects, including inhibition of neutrophil adhesion and oxidative burst, suppression of pro-inflammatory cytokine production (e.g., TNF-α, IL-6), and promotion of vasodilation.
• Inhibition of Methylation Reactions: Depletion of folate cofactors may affect S-adenosylmethionine (SAM)-dependent methylation reactions. This could alter the methylation status of DNA and proteins, potentially influencing gene expression and immune cell function.
• Induction of Apoptosis in Activated T-Lymphocytes: Methotrexate may selectively promote apoptosis in activated, proliferating T-cells, contributing to its immunomodulatory effect in autoimmune conditions.

The relative contribution of these mechanisms to the clinical efficacy in rheumatoid arthritis and other inflammatory disorders remains an area of ongoing investigation, with adenosine release considered a predominant pathway.

Pharmacokinetics

The pharmacokinetic profile of methotrexate is complex and exhibits significant dose-dependence, influencing its therapeutic application and toxicity profile.

Absorption

Oral absorption of methotrexate is dose-dependent and saturable. At low doses (<25-30 mg/m²), absorption from the gastrointestinal tract is generally rapid and reasonably complete, with a bioavailability ranging from approximately 60% to 90%. Absorption occurs primarily in the proximal jejunum via the reduced folate carrier. At higher oral doses, absorption becomes less predictable, incomplete, and more variable between patients due to saturation of transport mechanisms. The time to reach peak plasma concentration (t_max) is typically 1 to 2 hours after an oral dose. To ensure reliable systemic exposure, particularly in oncology, parenteral administration (subcutaneous, intramuscular, or intravenous) is preferred for doses exceeding 25 mg/m².

Distribution

Methotrexate distributes widely into body tissues and fluids. The apparent volume of distribution is approximately 0.4 to 0.8 L/kg. The drug exhibits a triphasic elimination pattern following intravenous administration. The initial distribution phase is rapid. Methotrexate is approximately 50-60% bound to plasma proteins, primarily albumin. This binding is displaceable by other drugs such as salicylates, sulfonamides, and certain nonsteroidal anti-inflammatory drugs (NSAIDs), which can potentially increase free, active drug concentrations. Methotrexate distributes into third-space fluid collections, such as ascites or pleural effusions. This distribution can act as a reservoir from which the drug slowly re-enters the systemic circulation, potentially prolonging exposure and increasing toxicity. It also penetrates the blood-brain barrier, though penetration is limited; however, high-dose regimens or intrathecal administration are used to achieve therapeutic concentrations in the central nervous system for prophylaxis or treatment of meningeal leukemia.

Metabolism

Hepatic metabolism of methotrexate is limited. A small fraction (less than 10%) is metabolized to 7-hydroxymethotrexate by hepatic aldehyde oxidase. This metabolite is less potent as a DHFR inhibitor but may contribute to renal toxicity, particularly at high doses, due to its lower solubility in acidic urine. The primary metabolic activation occurs intracellularly via polyglutamation, as previously described, which is not a traditional hepatic metabolic pathway but a critical determinant of cellular pharmacology.

Excretion

Renal excretion is the dominant route of elimination for methotrexate and its metabolites. Excretion occurs via a combination of glomerular filtration and active tubular secretion. The drug is actively secreted in the proximal tubule by transporters such as the multidrug resistance protein 2 (MRP2) and the breast cancer resistance protein (BCRP). Consequently, renal function is the most critical determinant of methotrexate clearance. Impairment of renal function dramatically reduces clearance, leading to prolonged plasma half-life and a substantially increased risk of severe myelosuppression and mucositis. The terminal elimination half-life (t_1/2) is dose-dependent. For low doses, it is approximately 3 to 10 hours. Following high-dose infusions (>1 g/m²), the terminal half-life can extend to 8 to 15 hours or longer, especially if renal function is compromised. A small amount of methotrexate is excreted in bile, with minimal enterohepatic recirculation.

Dosing Considerations

Dosing is highly indication-specific. In oncology, high-dose regimens (e.g., 1-12 g/m² administered intravenously) are common, often followed by leucovorin (folinic acid) rescue. Leucovorin provides reduced folate to “rescue” normal cells from the effects of DHFR inhibition, allowing for higher, more effective doses against tumor cells while mitigating toxicity. In rheumatology and dermatology, low-dose weekly regimens (e.g., 7.5-25 mg once weekly) are standard, with no leucovorin rescue required. Daily dosing is avoided due to significantly increased toxicity. Therapeutic drug monitoring of plasma methotrexate concentrations is standard practice following high-dose therapy to guide leucovorin rescue duration and assess the risk of toxicity.

Therapeutic Uses/Clinical Applications

The clinical applications of methotrexate are broadly divided into two categories based on dosage: high-dose chemotherapy and low-dose immunomodulation.

Oncologic Indications (High-Dose)

• Acute Lymphoblastic Leukemia (ALL): A cornerstone of multi-agent induction, consolidation, and maintenance therapy for ALL. It is used in high-dose systemic regimens and intrathecally for central nervous system prophylaxis.
• Gestational Trophoblastic Neoplasia (GTN): Highly effective as first-line single-agent or combination therapy for non-metastatic and low-risk metastatic GTN.
• Primary Central Nervous System Lymphoma: Used in high-dose regimens, often with leucovorin rescue.
• Osteosarcoma: A key component of adjuvant and neoadjuvant chemotherapy, administered in very high doses.
• Breast Cancer, Head and Neck Cancers, Lung Cancer: Used in various combination chemotherapy protocols.
• Mycosis Fungoides (Cutaneous T-cell Lymphoma): Used as a systemic therapy.

Immunomodulatory Indications (Low-Dose Weekly)

• Rheumatoid Arthritis: First-line conventional synthetic DMARD and anchor drug for most treatment strategies. It reduces disease activity, slows radiographic progression, and improves physical function.
• Psoriasis and Psoriatic Arthritis: Effective for moderate-to-severe plaque psoriasis and for the articular manifestations of psoriatic arthritis.
• Juvenile Idiopathic Arthritis (JIA): A standard first-line systemic agent for polyarticular JIA.
• Systemic Lupus Erythematosus (SLE): Used for managing musculoskeletal and cutaneous manifestations, and as a steroid-sparing agent.
• Inflammatory Bowel Disease (IBD): Particularly used in Crohn’s disease for maintenance of remission, often in patients who are intolerant or have lost response to thiopurines.
• Vasculitides: Such as Takayasu arteritis and granulomatosis with polyangiitis, often as a remission-maintenance agent.

Other Approved and Common Off-Label Uses

• Ectopic Pregnancy: Used as a medical management option for stable, unruptured ectopic pregnancies.
• Medical Abortion: Used in combination with misoprostol for early pregnancy termination.
• Steroid-Dependent Asthma: Used as a steroid-sparing agent in severe cases.
• Chronic Graft-Versus-Host Disease (cGVHD): Used for prophylaxis and treatment.

Adverse Effects

The adverse effect profile of methotrexate is extensive and correlates with dose, frequency, and patient-specific factors such as renal function and folate status. Adverse effects can be categorized as acute, chronic, or idiosyncratic.

Common Side Effects

• Gastrointestinal: Nausea, vomiting, anorexia, and stomatitis/mucositis are frequent, particularly with higher doses. These effects are often managed with antiemetics, dose adjustment, or switching to parenteral administration.
• Myelosuppression: Dose-related suppression of bone marrow function can lead to leukopenia, thrombocytopenia, and anemia. This is a major dose-limiting toxicity in oncology and requires regular monitoring of complete blood counts.
• Hepatotoxicity: Elevated liver transaminases are common. Chronic, low-dose therapy can lead to hepatic fibrosis and cirrhosis, although this risk appears lower with current dosing and monitoring guidelines. Risk factors include alcohol use, obesity, diabetes, and pre-existing liver disease.
• Pulmonary Toxicity: A hypersensitivity pneumonitis can occur, presenting with dry cough, dyspnea, fever, and interstitial infiltrates on imaging. This can be acute or insidious and may be life-threatening.

Serious and Rare Adverse Reactions

• Renal Toxicity: High-dose methotrexate can cause acute kidney injury due to precipitation of the drug and its less soluble metabolite, 7-hydroxymethotrexate, in the renal tubules, especially in acidic urine. Vigorous hydration and urinary alkalinization are preventive measures.
• Neurotoxicity: Associated with intrathecal or very high intravenous doses. Can present as acute chemical arachnoiditis, stroke-like syndromes, or a chronic leukoencephalopathy.
• Severe Dermatologic Reactions: Including Stevens-Johnson syndrome and toxic epidermal necrolysis, though rare.
• Opportunistic Infections: Due to myelosuppression and immunomodulation, there is an increased risk of infections, including reactivation of latent tuberculosis or hepatitis B.
• “Methotrexate Nodulosis”: Development of accelerated nodule formation in patients with rheumatoid arthritis.

Black Box Warnings

Methotrexate carries several black box warnings from the U.S. Food and Drug Administration, emphasizing its potentially fatal toxicities:

1. Severe, sometimes fatal, bone marrow suppression, aplastic anemia, and gastrointestinal toxicity. These risks are dose-related and more common with daily dosing.
2. Potentially fatal opportunistic infections, especially Pneumocystis jirovecii pneumonia.
3. Methotrexate elimination is reduced in patients with impaired renal function, ascites, or pleural effusions, leading to excessive toxicity. Dose must be adjusted or avoided based on renal function.
4. Life-threatening or fatal dermatologic reactions.
5. Fetal death and congenital abnormalities when used in pregnancy. It is contraindicated in pregnancy.
6. Serious, sometimes fatal hepatotoxicity, fibrosis, and cirrhosis. Risk increases with total cumulative dose, alcohol consumption, and other hepatotoxic exposures.
7. Potentially fatal pulmonary toxicity, which may occur acutely at any time during therapy.

Drug Interactions

Methotrexate is involved in numerous clinically significant drug interactions, primarily through pharmacokinetic mechanisms.

Major Drug-Drug Interactions

• NSAIDs, Salicylates, and Other Protein-Bound Drugs: These agents can displace methotrexate from plasma protein binding, potentially increasing free drug concentration. More importantly, many NSAIDs (e.g., ibuprofen, naproxen, ketoprofen) and salicylates inhibit renal prostaglandin synthesis, which can reduce renal blood flow and impair the active tubular secretion of methotrexate. This combination, particularly with high-dose methotrexate, can lead to dangerously elevated methotrexate levels and severe toxicity. Caution is advised even with low-dose methotrexate.
• Probenecid: Inhibits the renal tubular secretion of methotrexate, significantly reducing its clearance and increasing toxicity risk.
• Trimethoprim-Sulfamethoxazole and Other Dihydrofolate Reductase Inhibitors: Trimethoprim is a weak DHFR inhibitor. Concomitant use with methotrexate produces additive antifolate effects, markedly increasing the risk of myelosuppression and megaloblastic anemia.
• Penicillins (e.g., Piperacillin, Amoxicillin): May reduce the renal clearance of methotrexate, potentially by competing for tubular secretion.
• Nephrotoxic Agents (e.g., Aminoglycosides, Cyclosporine, Cisplatin): Can impair renal function and thereby reduce methotrexate clearance.
• Hepatotoxic Agents (e.g., Acitretin, Leflunomide, Azathioprine, Alcohol): Increase the risk of additive liver damage.
• Live Vaccines: Methotrexate is immunosuppressive; administration of live attenuated vaccines (e.g., MMR, varicella, yellow fever) carries a risk of disseminated vaccine-derived infection.

Contraindications

Absolute contraindications to methotrexate therapy include:

• Pregnancy, breastfeeding, and in men and women attempting to conceive (due to teratogenicity and gonadotoxicity).
• Significant renal impairment (creatinine clearance often <30-40 mL/min, depending on indication and dose).
• Pre-existing severe hepatic disease or alcoholism.
• Pre-existing blood dyscrasias, such as bone marrow hypoplasia, leukopenia, thrombocytopenia, or significant anemia.
• Hypersensitivity to methotrexate.
• Concurrent administration of live vaccines.

Special Considerations

Use in Pregnancy and Lactation

Methotrexate is a known teratogen (Pregnancy Category X) and abortifacient. Exposure during the first trimester is associated with a characteristic pattern of congenital anomalies termed “methotrexate embryopathy,” which may include cranial dysostosis, hypertelorism, wide nasal bridge, micrognathia, limb abnormalities, and growth retardation. It is contraindicated in pregnancy. Women of childbearing potential and men must use effective contraception during therapy and for a period after discontinuation. Recommendations vary but often suggest a waiting period of at least one ovulatory cycle for women and 3 months for men after stopping methotrexate before attempting conception. Methotrexate is excreted in breast milk and may accumulate in the infant due to immature renal function; breastfeeding is contraindicated.

Pediatric Considerations

Methotrexate is used extensively in pediatric oncology (e.g., ALL) and rheumatology (JIA). Dosing is typically based on body surface area (mg/m²) for high-dose therapy and on weight or body surface area for low-dose therapy. Pharmacokinetics may differ from adults, but the fundamental principles of mechanism, toxicity, and monitoring apply. Special attention is required for long-term survivors of childhood cancer treated with high-dose methotrexate, who may be at risk for chronic neurocognitive deficits and other late effects.

Geriatric Considerations

Elderly patients often have age-related declines in renal function and may have reduced folate stores. They are at increased risk for myelosuppression, mucositis, and hepatotoxicity. Renal function must be assessed carefully (using Cockcroft-Gault or similar estimation, not just serum creatinine), and doses should be initiated at the lower end of the recommended range. Concomitant medications that interact with methotrexate are also more common in this population.

Renal Impairment

Renal function is the paramount factor determining methotrexate clearance. Even mild renal impairment can significantly prolong the half-life of high-dose methotrexate, leading to profound toxicity. Methotrexate is contraindicated in patients with severe renal impairment. For patients with mild-to-moderate impairment, dose reductions are mandatory, and therapeutic drug monitoring is essential. The use of high-dose methotrexate is generally avoided if creatinine clearance is below 60-80 mL/min, depending on the protocol.

Hepatic Impairment

Methotrexate is contraindicated in patients with pre-existing severe hepatic disease due to the risk of exacerbating liver injury and potentially impairing metabolism/excretion. In patients with mild-to-moderate impairment, caution is advised, and therapy should be initiated at lower doses with close monitoring of liver function tests. Alcohol consumption should be strictly avoided.

Folate Supplementation

Administration of folic acid or folinic acid (leucovorin) is a critical component of methotrexate therapy to reduce toxicity without compromising efficacy in autoimmune diseases. For low-dose weekly regimens, daily folic acid supplementation (1-5 mg daily, or 5-10 mg once weekly taken at least 24 hours after the methotrexate dose) is standard practice. This reduces the incidence and severity of gastrointestinal side effects, stomatitis, and hepatic transaminase elevations. Folinic acid rescue is reserved for high-dose methotrexate regimens in oncology.

Summary/Key Points

• Methotrexate is an antifolate antimetabolite that inhibits dihydrofolate reductase, depleting reduced folate cofactors and disrupting de novo synthesis of thymidylate and purines, leading to impaired DNA/RNA synthesis.
• Intracellular polyglutamation leads to prolonged retention and broadened enzyme inhibition, while extracellular adenosine release is a key proposed mechanism for its low-dose immunomodulatory effects.
• Pharmacokinetics are dose-dependent: oral absorption saturates at higher doses, distribution includes third-space fluids, and renal excretion is the primary route of elimination, making renal function critical for dosing and toxicity risk.
• Therapeutic applications are dichotomized: high-dose (with leucovorin rescue) for malignancies like ALL and osteosarcoma, and low-dose weekly for autoimmune diseases like rheumatoid arthritis and psoriasis.
• The adverse effect profile is broad and serious, including myelosuppression, hepatotoxicity, pulmonary fibrosis, mucositis, and renal toxicity. It carries multiple black box warnings.
• Significant drug interactions occur with NSAIDs, salicylates, probenecid, trimethoprim-sulfamethoxazole, and nephrotoxic agents, primarily through competition for renal tubular secretion or additive toxicities.
• Methotrexate is a potent teratogen and abortifacient, absolutely contraindicated in pregnancy and breastfeeding. It requires dose adjustment in renal and hepatic impairment and in the elderly.
• Routine supplementation with folic acid is standard with low-dose therapy to mitigate toxicity, while folinic acid rescue is essential following high-dose administration.

Clinical Pearls

• Dosing Frequency is Critical: Low-dose methotrexate for autoimmune diseases must be administered once weekly. Daily administration dramatically increases toxicity and can be fatal.
• Monitor Before and During: Baseline and periodic monitoring must include complete blood count, comprehensive metabolic panel (renal and hepatic function), and for those with risk factors, hepatitis B and C serology and chest imaging if pulmonary symptoms arise.
• Renal Function is Paramount: Always calculate creatinine clearance (e.g., Cockcroft-Gault) before initiating or adjusting dose, not just rely on serum creatinine. Avoid or drastically reduce dose in renal impairment.
• Educate the Patient: Patients must be clearly instructed on the once-weekly schedule, the importance of folic acid, the signs of toxicity (e.g., sore throat, mouth ulcers, shortness of breath), and the necessity of effective contraception.
• High-Dose Requires Protocol: High-dose methotrexate is a medical procedure requiring inpatient or closely supervised administration, vigorous hydration, urinary alkalinization, and precise leucovorin rescue guided by serial serum methotrexate levels.

References

1. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
2. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
3. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
4. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
5. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
6. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
7. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
8. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.